Clinical trials: IBS
Irritable Bowel Syndrome, Placebo Effect
Effects of Open-label vs Double-blind Treatment in IBS
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
- Conditions
- Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil
- Trial name
- NCT02802241
- Testing
- peppermint oil
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Beth Israel Deaconess Medical Center
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Efficacy and Safety of IBS Digital Behavioral Treatment
A Randomized, Double-Blind, Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Self-administered behavioral treatments for Adult Subjects with Symptomatic Irritable Bowel Syndrome (IBS).
- Trial name
- EASITx (NCT04133519)
- Testing
- Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD), Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
- Where
- United States
- Volunteers
- 378 people
- Sponsor
- metaMe Health
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
To compare with a randomized trial (n=15 per treatment group), effects of colesevelam and placebo treatment, on colonic transit, bowel functions, permeability and tight junction expression in rectosigmoid mucosa of IBS-D with…
- Conditions
- Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
- Trial name
- NCT03270085
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
The primary goal of the proposed trial is to assess the short- and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome using two treatment delivery systems (self administered, therapist…
- Trial name
- NCT00738920
- Testing
- Self Administered Cognitive Behavior Therapy, Therapist Administered Cognitive Behavior Therapy, Behavioral Education and Supportive Therapy
- Where
- 2 sites in United States
- Volunteers
- 436 people
- Sponsor
- State University of New York at Buffalo
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
Constipation
B. Lactis HN019 for Functional Constipation
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
- Trial name
- CTT (NCT01463293)
- Testing
- B. lactis HN019
- Where
- 12 sites in United States
- Volunteers
- 224 people
- Sponsor
- Fonterra Research Centre
IBS - Irritable Bowel Syndrome
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines.
- Trial name
- NCT03983434
- Testing
- Inulin
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
IBS, Constipation
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
This study aims to determine the most effective treatment with Transcutaneous Electrical Acustimulation (TEA) for Irritable Bowel Syndrome with Constipation (IBS-C) by comparing efficacy between 5 separate sessions.
- Trial name
- TEA (NCT04953728)
- Testing
- Transcutaneous Electrical Acustimulation (TEA)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Colon Cancer, IBS
Patient Satisfaction With Propofol for Out Patient Colonoscopy
The primary purpose of this study is to determine if patient satisfaction with propofol is better than with non-propofol anesthesia for outpatient colonoscopies.
- Conditions
- Colon Cancer, IBS, Polyps
- Trial name
- NCT02937506
- Testing
- Propofol, Fentanyl Plus Midazolam
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Mount Carmel Health System
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Functional Abdominal Pain, Functional Dyspepsia
Efficacy of Open Label Placebo in Children With FGIDs
This study is aimed at investigating the efficacy of placebo for symptom relief in children with abdominal pain related functional gastrointestinal disorders.
- Conditions
- Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
- Trial name
- Placebo (NCT02389998)
- Testing
- Hyoscyamine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Boston Children's Hospital
Constipation Predominant Irritable Bowel Syndrome
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria.
- Trial name
- T3MPO-3 (NCT02727751)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Ardelyx